2seventy bio’s heritage is anchored in deep care for patients and our people, thought leadership, and scientific expertise from our gene therapy and oncology roots. The company was spun out of bluebird bio, Inc., a pioneer in gene and cell therapy that has developed and delivered four commercial medicines for severe genetic diseases and cancer.

In early 2021, bluebird announced its decision to make a radical shift that would allow for more rapid and efficient scientific progress across both the gene therapy and cell therapy business units by separating the company. bluebird bio would continue its focus on gene therapy and a new independent public company, 2seventy bio, would emerge to focus on oncology cell therapy.

Launched in late 2021, 2seventy bio doubled-down on support for the commercial success of its partnered therapy with Bristol Myers Squibb, Abecma, idecabtagene vicleucel (ide-cel), in multiple myeloma and continued development of its own cell therapy pipeline. The company expanded partnerships with several industry peers including Regeneron, Novo Nordisk, and JW Therapeutics. The pipeline grew further with the team making steady progress with key R&D candidates in B cell non-Hodgkin lymphoma, acute myeloid leukemia, and ovarian cancer.

In early 2024, 2seventy made a strategic decision to prioritize resources and capital towards maximizing the potential of Abecma. In support of the Abecma strategic focus, the Company sold the R&D pipeline to existing partner Regeneron, in exchange for upfront economics and downstream milestones and royalties.

Today, 2seventy is comprised of a streamlined team of approximately 65 employees focused exclusively on making Abecma available to more multiple myeloma patients and delivering on our mission of creating more time for patients.